JP2016504365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504365A5 JP2016504365A5 JP2015550767A JP2015550767A JP2016504365A5 JP 2016504365 A5 JP2016504365 A5 JP 2016504365A5 JP 2015550767 A JP2015550767 A JP 2015550767A JP 2015550767 A JP2015550767 A JP 2015550767A JP 2016504365 A5 JP2016504365 A5 JP 2016504365A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- compound
- heterocyclyl
- heteroaryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- -1 heteroaryl aryl Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 claims 1
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261747052P | 2012-12-28 | 2012-12-28 | |
| US61/747,052 | 2012-12-28 | ||
| PCT/US2013/077804 WO2014105952A2 (en) | 2012-12-28 | 2013-12-26 | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016504365A JP2016504365A (ja) | 2016-02-12 |
| JP2016504365A5 true JP2016504365A5 (enExample) | 2016-11-24 |
Family
ID=49958735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015550767A Pending JP2016504365A (ja) | 2012-12-28 | 2013-12-26 | Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9802904B2 (enExample) |
| EP (1) | EP2938610A2 (enExample) |
| JP (1) | JP2016504365A (enExample) |
| AU (1) | AU2013370417A1 (enExample) |
| CA (1) | CA2896731A1 (enExample) |
| WO (1) | WO2014105952A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| MA41291A (fr) * | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| HK1248222A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂 |
| HK1248220A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂 |
| EP3377493B1 (en) | 2015-11-20 | 2020-04-08 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| CA3014192A1 (en) * | 2016-02-12 | 2017-08-17 | Forma Therapeutics, Inc. | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors |
| US10889592B2 (en) | 2016-02-12 | 2021-01-12 | Valo Early Discovery, Inc. | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors |
| GB201604647D0 (en) * | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) * | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| KR102327053B1 (ko) * | 2017-03-16 | 2021-11-17 | 기초과학연구원 | 퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도 |
| KR101986013B1 (ko) * | 2017-08-04 | 2019-06-04 | 연세대학교 산학협력단 | Ml323을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물 |
| WO2019032863A1 (en) | 2017-08-11 | 2019-02-14 | Forma Therapeutics, Inc. | CARBOXAMIDES USED AS UBIQUITIN SPECIFIC PROTEASE INHIBITORS |
| WO2019089216A1 (en) * | 2017-11-01 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers |
| EP3833441A1 (en) | 2018-08-09 | 2021-06-16 | Valo Early Discovery, Inc. | Inhibiting deubiquitinase usp25 and usp28 |
| BR112021002408A2 (pt) | 2018-08-09 | 2021-05-04 | Valo Early Discovery, Inc. | carboxamidas como inibidores da protease específica de ubiquitina |
| AU2019405925B2 (en) | 2018-12-20 | 2025-07-03 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| JP7675020B2 (ja) * | 2019-05-31 | 2025-05-12 | ケース ウエスタン リザーブ ユニバーシティ | Ｂａｘ阻害剤およびその使用 |
| CN110699453B (zh) * | 2019-10-10 | 2020-09-01 | 山东大学第二医院 | 一种胆管癌检测、治疗和预后靶点及应用 |
| ES3025474T3 (en) | 2020-01-15 | 2025-06-09 | Ksq Therapeutics Inc | Compositions of substituted pyrazolopyrimidines and uses thereof |
| KR102481705B1 (ko) | 2020-08-04 | 2022-12-27 | 연세대학교 산학협력단 | 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물 |
| AU2021371305A1 (en) | 2020-10-30 | 2023-06-15 | KSQ Therapeutics, Inc. | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
| CN114436976B (zh) * | 2021-01-29 | 2023-07-11 | 石药集团中奇制药技术（石家庄）有限公司 | 一种新型喹唑啉类衍生物及其制备和应用 |
| WO2022199652A1 (en) * | 2021-03-24 | 2022-09-29 | Impact Therapeutics (Shanghai) , Inc | Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof |
| IL307157A (en) * | 2021-04-07 | 2023-11-01 | Forma Therapeutics Inc | Ubiquitin-specific protease 1 (USP1) inhibition |
| CN113368112B (zh) * | 2021-05-10 | 2022-09-27 | 河南农业大学 | Usp1-uaf1抑制剂在制备药物中的应用，药物组合物 |
| AR127646A1 (es) | 2021-11-12 | 2024-02-14 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| EP4504341A1 (en) | 2022-04-08 | 2025-02-12 | Shy Therapeutics LLC | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN120794959A (zh) * | 2022-04-29 | 2025-10-17 | 江苏亚虹医药科技股份有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
| WO2024086790A1 (en) | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
| CN120202201A (zh) * | 2022-11-04 | 2025-06-24 | 深圳晶泰科技有限公司 | 泛素特异性蛋白酶1的抑制剂及其应用 |
| WO2024153175A1 (en) * | 2023-01-19 | 2024-07-25 | Laekna Therapeutics Shanghai Co., Ltd. | Heteroaromatic compounds and their use as usp1 inhibitors |
| TW202509030A (zh) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | 化合物及使用方法 |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| CN121693502A (zh) * | 2023-06-29 | 2026-03-17 | 艾健科学股份有限公司 | 新型嘧啶衍生物 |
| EP4741386A1 (en) * | 2023-07-05 | 2026-05-13 | Jiangsu Yahong Meditech Co., Ltd. | Pyrimidine compound, preparation method therefor and medical use thereof |
| CN121219283A (zh) * | 2023-07-05 | 2025-12-26 | 江苏亚虹医药科技股份有限公司 | 联嘧啶化合物的晶型及其制备方法和用途 |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| CN121532384A (zh) * | 2023-07-14 | 2026-02-13 | 来凯制药(宁波)有限公司 | 嘧啶化合物及其作为usp1抑制剂的用途 |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| WO2025129076A1 (en) * | 2023-12-15 | 2025-06-19 | Eikon Therapeutics, Inc. | Pyridopyrimidine and quinazoline derivatives as usp1 inhibitors, compositions comprising them and methods of using the same |
| WO2025129135A2 (en) * | 2023-12-15 | 2025-06-19 | Eikon Therapeutics, Inc. | Compositions comprising usp1 inhibitors and methods of using the same |
| WO2025151705A1 (en) | 2024-01-10 | 2025-07-17 | Vrise Therapeutics, Inc. | Novel inhibitors of dna damage repair pathway |
| CN121914116A (zh) * | 2024-10-22 | 2026-04-24 | 烟台新药创制山东省实验室 | 杂环酰胺类化合物、其制备方法及用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| JP2657760B2 (ja) * | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | ４−アミノキナゾリン誘導体およびそれを含有する医薬品 |
| DE19853278A1 (de) | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| ES2242839T3 (es) | 2001-04-20 | 2005-11-16 | Ciba Specialty Chemicals Holding Inc. | 4-amino-2- (piridin-2-il)pirimidina como sustancias activas microbicidas. |
| EP1254903B1 (en) | 2001-04-20 | 2005-06-08 | Ciba SC Holding AG | 4-Amino-2-(pyridin-2-yl)pyrimidine as microbicidal active substances |
| JPWO2003026661A1 (ja) * | 2001-09-14 | 2005-01-06 | 山之内製薬株式会社 | インスリン分泌促進剤及び新規なピリミジン誘導体 |
| CA2469316A1 (en) | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as gsk-3 inhibitors |
| AU2003214110A1 (en) * | 2002-03-15 | 2003-09-29 | Ciba Specialty Chemicals Holding Inc. | 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces |
| MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| MXPA06012130A (es) | 2004-04-20 | 2007-01-31 | Transtech Pharma Inc | Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina. |
| WO2006004589A2 (en) | 2004-05-08 | 2006-01-12 | Neurogen Corporation | 3-aryl-5,6-disubstituted pyridazines |
| KR20060079121A (ko) | 2004-12-31 | 2006-07-05 | 에스케이케미칼주식회사 | 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체 |
| US20070032499A1 (en) | 2005-08-05 | 2007-02-08 | Philippe Guedat | Novel cysteine protease inhibitors and their therapeutic applications |
| AU2007304195A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| JP2010208945A (ja) | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| US8637560B2 (en) | 2007-07-18 | 2014-01-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment |
| JP2011032169A (ja) | 2007-12-11 | 2011-02-17 | Genecare Research Institute Co Ltd | ４−アミノピリミジン誘導体および該化合物を含有する医薬組成物 |
| PH12012500097A1 (en) | 2009-07-21 | 2011-01-27 | Shanghai Inst Organic Chem | Potent small molecule inhibitors of autophagy, and methods of use thereof |
| AR077999A1 (es) * | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| MX336731B (es) | 2010-01-28 | 2016-01-28 | Harvard College | Composiciones y metodos para potenciar la actividad de proteasoma. |
| UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| EP2360158A1 (en) | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
| US9518032B2 (en) | 2010-04-30 | 2016-12-13 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of USP1 deubiquitinating enzyme activity |
| US8865708B2 (en) | 2010-05-07 | 2014-10-21 | California Institute Of Technology | Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase |
| EP2595993B1 (en) | 2010-07-23 | 2018-04-18 | President and Fellows of Harvard College | Tricyclic proteasome activity enhancing compounds |
| WO2012040527A2 (en) | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| WO2012061754A2 (en) | 2010-11-05 | 2012-05-10 | The Broad Institute, Inc. | Compounds and methods for treating autoimmune diseases |
| WO2012172043A1 (en) | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| ES2698847T3 (es) * | 2011-07-07 | 2019-02-06 | Merck Patent Gmbh | Azaheterociclos sustituidos para el tratamiento del cáncer |
| EP2546684A1 (fr) | 2011-07-15 | 2013-01-16 | ETA SA Manufacture Horlogère Suisse | Guide de lumière pour l'éclairage d'un dispositif d'affichage d'informations |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| JP2014237590A (ja) | 2011-09-30 | 2014-12-18 | アステラス製薬株式会社 | ２−（ピリジン−２−イル）ピリミジン−４−アミン化合物又はその塩 |
| PT2780326T (pt) | 2011-10-19 | 2019-03-04 | Vivolux Ab | Método para inibição da atividade da desubiquitinação |
| WO2013112706A1 (en) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| WO2013112699A2 (en) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| EP2938610A2 (en) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
-
2013
- 2013-12-26 EP EP13821618.9A patent/EP2938610A2/en not_active Withdrawn
- 2013-12-26 WO PCT/US2013/077804 patent/WO2014105952A2/en not_active Ceased
- 2013-12-26 AU AU2013370417A patent/AU2013370417A1/en not_active Abandoned
- 2013-12-26 US US14/655,538 patent/US9802904B2/en active Active
- 2013-12-26 JP JP2015550767A patent/JP2016504365A/ja active Pending
- 2013-12-26 CA CA2896731A patent/CA2896731A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531041A5 (enExample) | ||
| EA201201677A1 (ru) | Производные гетероарилимидазолона в качестве ингибиторов jak | |
| EA201200938A1 (ru) | Производные имидазопиридина в качестве ингибиторов jak | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| JP2016503799A5 (enExample) | ||
| EA201201143A1 (ru) | Производные пиразола в качестве ингибиторов jak | |
| PE20081888A1 (es) | ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3 | |
| JP2014500870A5 (enExample) | ||
| EA201301319A1 (ru) | Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний | |
| JP2014508811A5 (enExample) | ||
| CO6290714A2 (es) | Compuestos organicos | |
| CL2008001230A1 (es) | Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis. | |
| JP2012153722A5 (enExample) | ||
| EA201000614A1 (ru) | Производные пурина как лиганды аденозинового рецептора а | |
| NZ590650A (en) | Buprenorphine analogs | |
| EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов | |
| RU2015135722A (ru) | Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение | |
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| JP2017510660A5 (enExample) | ||
| JP2017511321A5 (enExample) | ||
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| JP2016537382A5 (enExample) | ||
| JP2015502367A5 (enExample) | ||
| JP2012512863A5 (enExample) |